SCHEMBL3868079

SCHEMBL3868079

Cc1ccc(S(=O)(=O)OCC2CCN(S(=O)(=O)c3ccc(C)cc3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
KDM4E B2RXH2 2/20 0.56
PKM P14618 3/20 0.55
HTT P42858 2/20 0.55
POLB P06746 1/20 0.55
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
LMNA P02545 2/20 0.51
EBP Q15125 1/20 0.51
DHCR7 Q9UBM7 1/20 0.51
GAA P10253 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23387563 0.90 CYP2C19 (0.50) ALDH1A1KDM4EPKMHTTPOLB
SCHEMBL13922213 0.87 CYP2D6 (0.58) ALDH1A1KDM4EPKMHTTPOLB
SCHEMBL20300360 0.86 KMT2A (0.59) ALDH1A1KDM4EPKMHTTPOLB
SCHEMBL26655196 0.86 CYP2D6 (0.45) ALDH1A1MEN1KMT2AGAACYP3A4
SCHEMBL26655167 0.86 CYP2D6 (0.45) ALDH1A1MEN1KMT2AGAACYP3A4
SCHEMBL7166740 0.86 CYP2D6 (0.45) ALDH1A1MEN1KMT2AGAACYP3A4
SCHEMBL7032005 0.86 CYP2D6 (0.45) ALDH1A1MEN1KMT2AGAACYP3A4
SCHEMBL3880694 0.85 HTR2A (0.55) ALDH1A1KDM4EPKMHTTPOLB
SCHEMBL10459117 0.85 ALDH1A1 (0.57) ALDH1A1KDM4EPKMHTTPOLB
SCHEMBL13922018 0.85 ALDH1A1 (0.58) ALDH1A1KDM4EPKMPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491727-B2 Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches EPIX DELAWARE, INC. (US) 2009-02-17 US disclosed
US-7491727-B2 Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches EPIX DELAWARE, INC. (US) 2009-02-17 US disclosed
US-7491727-B2 Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches EPIX DELAWARE, INC. (US) 2009-02-17 US disclosed
US-7488731-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2009-02-10 US disclosed
US-7488731-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2009-02-10 US disclosed
US-7488731-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2009-02-10 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. 2008-08-21 US disclosed
WO-2008073623-A2 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2008-06-19 WO disclosed
US-20080027066-A1 Arylpiperazinyl Compounds EPIX DELAWARE, INC. 2008-01-31 US disclosed
US-20070004742-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2007-01-04 US disclosed
US-7153858-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2006-12-26 US disclosed
EP-1592425-A2 NEW ARYLPIPERAZINYL COMPOUNDS Predix Pharmaceuticals Holdings, Inc. (US) 2005-11-09 EP disclosed
WO-2004069794-A9 NEW ARYLPIPERAZINYL COMPOUNDS PREDIX PHARMACEUTICALS HOLDING (US) 2004-12-09 WO disclosed
US-20040220192-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2004-11-04 US disclosed
WO-2004069794-A2 NEW ARYLPIPERAZINYL COMPOUNDS PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2004-08-19 WO disclosed
US-5607950-A IRRITABLE BOWEL SYNDROME PFIZER INC. (US) 1997-03-04 US disclosed
EP-0508988-B1 MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LTD (GB) 1994-03-02 EP disclosed
EP-0508988-A1 MUSCARINIC RECEPTOR ANTAGONISTS. PFIZER LTD (GB) 1992-10-21 EP disclosed
WO-1991010647-A1 MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 1991-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027066-A1 Arylpiperazinyl Compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885KDM4E 3482/4885PKM 2188/4885
US-20070004742-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885KDM4E 3482/4885PKM 2188/4885
US-20080200467-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 ALDH1A1 519/4885KDM4E 905/4885PKM 1473/4885
US-20040220192-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885KDM4E 3482/4885PKM 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.